David M Margolis MD
HIV/AIDS Medicine
Professor, Medicine, University of North Carolina at Chapel Hill School of Medicine
Join to View Full Profile
101 Manning DrChapel Hill, NC 27599
Phone+1 984-974-7198
Dr. Margolis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Massachusetts Medical SchoolPost-Doctoral Fellowship, 1991 - 1994
National Institutes of Health Clinical CenterFellowship, Infectious Disease, 1988 - 1991
Tufts Medical CenterResidency, Internal Medicine, 1985 - 1988
Tufts University School of MedicineClass of 1985
Certifications & Licensure
NC State Medical License 2005 - 2025
TX State Medical License 2001 - 2006
MD State Medical License 1989 - 2001
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- Fellow AAAS, 2022
- Elected Member Association of American Physicians, 2019
- Elected Member The American Society for Clinical Investigation, 2005
- Join now to see all
Clinical Trials
Publications & Presentations
PubMed
- Two phase 1 studies of safety, tolerability, and pharmacokinetics of an EFdA prodrug (BRII-732) in healthy adult participants.David Margolis, Michael Watkins, Yali Zhu
Antimicrobial Agents and Chemotherapy. 2025-04-22 - 2 citationsBET degraders reveal BRD4 disruption of 7SK and P-TEFb is critical for effective reactivation of latent HIV in CD4+ T-cells.Anne-Marie W Turner, Frances M Bashore, Shane D Falcinelli, Joshua A Fox, Alana L Keller
Journal of Virology. 2025-04-15 - A targeted CRISPR screen identifies ETS1 as a regulator of HIV-1 latency.Manickam Ashokkumar, Terry L Hafer, Abby Felton, Nancie M Archin, David M Margolis
Plos Pathogens. 2025-04-01
Journal Articles
- The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Post-Treatment Controllers Identified from 14 Clinical StudiesElizabeth Connick, Michael C Sneller, Jonathan Z Li, Paul Volberding, Daniel R Kuritzkes, Robert T Schooley, David Margolis, Daniel Skiest, John W Mellors, Ronald Mits..., The Journal of Infectious Diseases
Press Mentions
Brii Biosciences Announces Positive Data Demonstrating Its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 SubvariantsJuly 27th, 2022- Brii Bio Announces Positive Data Demonstrating Its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 SubvariantMay 9th, 2022
- Why COVID-19 Cases May Continue to Decline in the United StatesApril 7th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
